Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + palbociclib + pertuzumab + trastuzumab
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intramuscular, Oral, Intravenous, Subcutaneous
01
Overview
A combination therapy regimen consisting of four distinct agents targeting multiple cancer pathways: fulvestrant (an estrogen receptor antagonist), palbociclib (a CDK4/6 inhibitor), and the dual HER2-targeted antibodies pertuzumab and trastuzumab. This combination approach is designed for HER2-positive breast cancer, particularly in cases that are also hormone receptor positive. The pertuzumab and trastuzumab components bind to different domains of HER2, creating a synergistic effect in blocking HER2 signaling pathways.
02
Targets
HER2 ECD II (Human epidermal growth factor receptor 2 domain II)CDK4 (Cyclin-dependent kinase 4)ESR1 (ERα)CDK6 (Cyclin-dependent kinase 6)GPER1 (G protein-coupled estrogen receptor 1)ESR2 (ERβ)
Beyond the preview
Go deeper on fulvestrant + palbociclib + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + palbociclib + pertuzumab + trastuzumab.